240 related articles for article (PubMed ID: 36853604)
1. Assessment of Sex Disparities in Nonacceptance of Statin Therapy and Low-Density Lipoprotein Cholesterol Levels Among Patients at High Cardiovascular Risk.
Brown CJ; Chang LS; Hosomura N; Malmasi S; Morrison F; Shubina M; Lan Z; Turchin A
JAMA Netw Open; 2023 Feb; 6(2):e231047. PubMed ID: 36853604
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk.
Kohli-Lynch CN; Bellows BK; Thanassoulis G; Zhang Y; Pletcher MJ; Vittinghoff E; Pencina MJ; Kazi D; Sniderman AD; Moran AE
JAMA Cardiol; 2019 Oct; 4(10):969-977. PubMed ID: 31461121
[TBL] [Abstract][Full Text] [Related]
3. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
[TBL] [Abstract][Full Text] [Related]
4. Association Between Achieved Low-Density Lipoprotein Levels and Major Adverse Cardiac Events in Patients With Stable Ischemic Heart Disease Taking Statin Treatment.
Leibowitz M; Karpati T; Cohen-Stavi CJ; Feldman BS; Hoshen M; Bitterman H; Suissa S; Balicer RD
JAMA Intern Med; 2016 Aug; 176(8):1105-13. PubMed ID: 27322095
[TBL] [Abstract][Full Text] [Related]
5. Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.
Marrett E; Zhao C; Zhang NJ; Zhang Q; Ramey DR; Tomassini JE; Tershakovec AM; Neff DR
Vasc Health Risk Manag; 2014; 10():237-46. PubMed ID: 24851051
[TBL] [Abstract][Full Text] [Related]
6. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.
Willeit P; Ridker PM; Nestel PJ; Simes J; Tonkin AM; Pedersen TR; Schwartz GG; Olsson AG; Colhoun HM; Kronenberg F; Drechsler C; Wanner C; Mora S; Lesogor A; Tsimikas S
Lancet; 2018 Oct; 392(10155):1311-1320. PubMed ID: 30293769
[TBL] [Abstract][Full Text] [Related]
7. A Long-term Benefit Approach vs Standard Risk-Based Approaches for Statin Eligibility in Primary Prevention.
Thanassoulis G; Sniderman AD; Pencina MJ
JAMA Cardiol; 2018 Nov; 3(11):1090-1095. PubMed ID: 30422172
[TBL] [Abstract][Full Text] [Related]
8. Relative contributions of statin intensity, achieved low-density lipoprotein cholesterol level, and statin therapy duration to cardiovascular risk reduction in patients with type 2 diabetes: population based cohort study.
Kim JY; Choi J; Kim SG; Kim NH
Cardiovasc Diabetol; 2022 Feb; 21(1):28. PubMed ID: 35193571
[TBL] [Abstract][Full Text] [Related]
9. Quantifying Unmet Need in Statin-Treated Hyperlipidemia Patients and the Potential Benefit of Further LDL-C Reduction Through an EHR-Based Retrospective Cohort Study.
Schleyer T; Hui S; Wang J; Zhang Z; Knapp K; Baker J; Chase M; Boggs R; Simpson RJ
J Manag Care Spec Pharm; 2019 May; 25(5):544-554. PubMed ID: 31039062
[TBL] [Abstract][Full Text] [Related]
10. Sex disparity persists in the prevention of cardiovascular disease in women on statin therapy compared to that in men.
Moreno-Arellano S; Delgado-de-Mendoza J; Santi-Cano MJ
Nutr Metab Cardiovasc Dis; 2018 Aug; 28(8):810-815. PubMed ID: 29754716
[TBL] [Abstract][Full Text] [Related]
11. The therapeutic management of South African dyslipidaemic patients at very high cardiovascular risk (CARDIO TRACK): a cross-sectional study.
Blom DJ; Ranjith N; Joshi P; Naidoo P; van Tonder A; Musa MG; Joshi S; Leisegang R; Trokis JS; Makan H; Raal FJ
Cardiovasc J Afr; 2020; 31(5):245-251. PubMed ID: 33151240
[TBL] [Abstract][Full Text] [Related]
12. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.
Morieri ML; Perrone V; Veronesi C; Degli Esposti L; Andretta M; Plebani M; Fadini GP; Vigili de Kreutzenberg S; Avogaro A
Cardiovasc Diabetol; 2021 Jul; 20(1):144. PubMed ID: 34271920
[TBL] [Abstract][Full Text] [Related]
13. Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization. Perspectives from the CREDO-Kyoto registry cohort-2.
Natsuaki M; Furukawa Y; Morimoto T; Nakagawa Y; Ono K; Kaburagi S; Inada T; Mitsuoka H; Taniguchi R; Nakano A; Kita T; Sakata R; Kimura T;
Circ J; 2012; 76(6):1369-79. PubMed ID: 22447012
[TBL] [Abstract][Full Text] [Related]
14. Association of Strict Versus Lenient Cholesterol Lowering with Cardiac Outcomes, Diabetes Progression and Complications, and Mortality in Patients with Diabetes Treated with Statins: Is Less More?
Odeleye V; Masarweh O; Restrepo J; Alvarez CA; Mansi IA
Drug Saf; 2023 Nov; 46(11):1105-1116. PubMed ID: 37782373
[TBL] [Abstract][Full Text] [Related]
15. The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events.
Puri R; Nissen SE; Shao M; Kataoka Y; Uno K; Kapadia SR; Tuzcu EM; Nicholls SJ
Eur J Prev Cardiol; 2016 Mar; 23(5):474-85. PubMed ID: 25691546
[TBL] [Abstract][Full Text] [Related]
16. Statin Therapy in Patients With Low Serum Levels of Low-Density Lipoprotein Cholesterol.
Tsujimoto T; Kajio H; Sugiyama T
Am J Cardiol; 2017 Dec; 120(11):1947-1954. PubMed ID: 28951019
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of Dyslipidemia and Availability of Lipid-Lowering Medications Among Primary Health Care Settings in China.
Lu Y; Zhang H; Lu J; Ding Q; Li X; Wang X; Sun D; Tan L; Mu L; Liu J; Feng F; Yang H; Zhao H; Schulz WL; Krumholz HM; Pan X; Li J;
JAMA Netw Open; 2021 Sep; 4(9):e2127573. PubMed ID: 34586366
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
Toth PP; Foody JM; Tomassini JE; Sajjan SG; Ramey DR; Neff DR; Tershakovec AM; Hu XH; Tunceli K
J Clin Lipidol; 2014; 8(1):107-16. PubMed ID: 24528691
[TBL] [Abstract][Full Text] [Related]
19. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
20. Low-density lipoprotein cholesterol response after statin initiation among persons living with human immunodeficiency virus.
Burkholder GA; Muntner P; Zhao H; Mugavero MJ; Overton ET; Kilgore M; Drozd DR; Crane HM; Moore RD; Mathews WC; Geng E; Boswell S; Floris-Moore M; Rosenson RS
J Clin Lipidol; 2018; 12(4):988-998.e5. PubMed ID: 29853312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
